NCT05266846View on ClinicalTrials.gov

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

November 16, 2026

Study Completion Date

February 16, 2027

Conditions
ALK Gene MutationLung AdenocarcinomaImmunotherapy
Interventions
DRUG

Pembrolizumab injection

Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER